Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Non-Current Assets (2016 - 2026)

Wave Life Sciences (WVE) has disclosed Non-Current Assets for 12 consecutive years, with $22.3 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 26.66% year-over-year to $22.3 million; the TTM value through Mar 2026 reached $22.3 million, down 26.66%, while the annual FY2025 figure was $23.7 million, 25.55% down from the prior year.
  • Non-Current Assets hit $22.3 million in Q1 2026 for Wave Life Sciences, down from $23.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $53.2 million in Q2 2022 and bottomed at $22.3 million in Q1 2026.
  • Average Non-Current Assets over 5 years is $37.6 million, with a median of $38.5 million recorded in 2024.
  • Year-over-year, Non-Current Assets rose 17.76% in 2022 and then decreased 26.66% in 2026.
  • Wave Life Sciences' Non-Current Assets stood at $47.8 million in 2022, then dropped by 17.29% to $39.6 million in 2023, then fell by 19.62% to $31.8 million in 2024, then decreased by 25.55% to $23.7 million in 2025, then dropped by 5.97% to $22.3 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $22.3 million, $23.7 million, and $25.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.